258 related articles for article (PubMed ID: 17998597)
1. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.
Jakóbkiewicz-Banecka J; Wegrzyn A; Wegrzyn G
J Appl Genet; 2007; 48(4):383-8. PubMed ID: 17998597
[TBL] [Abstract][Full Text] [Related]
2. Substrate reduction therapy of glycosphingolipid storage disorders.
Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
[TBL] [Abstract][Full Text] [Related]
3. Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.
Coutinho MF; Santos JI; Alves S
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27384562
[TBL] [Abstract][Full Text] [Related]
4. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann RH
Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
[TBL] [Abstract][Full Text] [Related]
5. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
[TBL] [Abstract][Full Text] [Related]
6. Substrate reduction therapy.
Platt FM; Jeyakumar M
Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
[TBL] [Abstract][Full Text] [Related]
7. Substrate reduction therapy for glycosphingolipid storage disorders.
Lachmann RH; Platt FM
Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
[TBL] [Abstract][Full Text] [Related]
8. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Jeyakumar M; Butters TD; Dwek RA; Platt FM
Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
[TBL] [Abstract][Full Text] [Related]
9. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
Butters TD; Dwek RA; Platt FM
Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
[TBL] [Abstract][Full Text] [Related]
11. Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement.
Pastores GM
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):77-82. PubMed ID: 18221193
[TBL] [Abstract][Full Text] [Related]
12. AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.
Nascimbeni F; Dionisi Vici C; Vespasiani Gentilucci U; Angelico F; Nobili V; Petta S; Valenti L;
Dig Liver Dis; 2020 Apr; 52(4):359-367. PubMed ID: 31902560
[TBL] [Abstract][Full Text] [Related]
13. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
14. [Current therapeutic strategies in lysosomal disorders].
Kaminsky P; Lidove O
Presse Med; 2014 Nov; 43(11):1174-84. PubMed ID: 24863660
[TBL] [Abstract][Full Text] [Related]
15. Substrate reduction therapy for lysosomal storage diseases.
Cox TM
Acta Paediatr Suppl; 2005 Mar; 94(447):69-75; discussion 57. PubMed ID: 15895716
[TBL] [Abstract][Full Text] [Related]
16. Overcoming the Next Barriers to Successful Therapy.
Cohen IJ; Baris H; Mistry PK; Sands MS
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
[No Abstract] [Full Text] [Related]
17. Substrate reduction therapy in the infantile form of Tay-Sachs disease.
Bembi B; Marchetti F; Guerci VI; Ciana G; Addobbati R; Grasso D; Barone R; Cariati R; Fernandez-Guillen L; Butters T; Pittis MG
Neurology; 2006 Jan; 66(2):278-80. PubMed ID: 16434676
[TBL] [Abstract][Full Text] [Related]
18. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones.
Arfi A; Richard M; Gandolphe C; Scherman D
J Inherit Metab Dis; 2010 Feb; 33(1):61-7. PubMed ID: 20084460
[TBL] [Abstract][Full Text] [Related]
19. The molecular basis of lysosomal storage diseases and their treatment.
Winchester B; Vellodi A; Young E
Biochem Soc Trans; 2000 Feb; 28(2):150-4. PubMed ID: 10816117
[TBL] [Abstract][Full Text] [Related]
20. [How does the landscape change in lysosomal storage disease].
Parini R
Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
